← Back to Search

Unknown

LY3871801 + Repaglinide + Drug Cocktail (Part 2) for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up predose up to 96 hours postdose

Awards & highlights

Study Summary

This trial studies the effects of LY3871801 when taken orally in healthy people, and its effect on other drugs in the body. Adverse effects and tolerability will be monitored. Trial may last up to 25 days.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ predose up to 96 hours postdose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~predose up to 96 hours postdose

This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 96 hours postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Methotrexate

Dextromethorphan

+7 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: LY3871801 + Repaglinide + Drug Cocktail (Part 2)Experimental Treatment5 Interventions

LY3871801 administered orally in combination with repaglinide given orally and drug cocktail which includes warfarin, dextromethorphan and midazolam administered orally.

Group II: LY3871801 + Methotrexate (Part 1)Experimental Treatment2 Interventions

LY3871801 administered orally in combination with methotrexate given orally.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

LY3871801

2022

Completed Phase 1

~90

Repaglinide

2016

Completed Phase 4

~7040

Warfarin

2017

Completed Phase 4

~248220

Midazolam

2018

Completed Phase 4

~1910

Methotrexate

2013

Completed Phase 4

~3800

Dextromethorphan

2019

Completed Phase 4

~920

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor

2,615 Previous Clinical Trials

3,201,019 Total Patients Enrolled

Study DirectorEli Lilly and Company

1,344 Previous Clinical Trials

405,213 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the combination of LY3871801, Repaglinide and Drug Cocktail (Part 2) been given regulatory approval?

"Limited clinical data is available to support the safety and efficacy of LY3871801 + Repaglinide + Drug Cocktail (Part 2), so it was given a score of 1."

Answered by AI

What is the cap on participants for this trial?

"Indeed, clinicaltrials.gov lists this medical trial as actively seeking participants. It was first published on November 2nd 2022 and most recently updated on the 22nd of that same month. 40 patients need to be sourced from 1 location for the study's completion."

Answered by AI

Is enrollment available to those below the age of 75?

"This medical trial demands that participants are of legal age and within 65 years old in order to meet the set inclusion criteria."

Answered by AI

Does my personal profile meet the criteria for participation in this research effort?

"This trial is open to 40 adults, aged 18-65 with a BMI between 18.5 and 40 and body weight of at least 45 kilograms. To be eligible for enrolment into this study, candidates must also pass medical assessments that demonstrate their general healthiness as well as not being part of the childbearing population (for Part 2)."

Answered by AI

Is enrollment available for this experiment at present?

"Affirmative. The clinical trial details available on the website of clinicaltrials.gov verify that this medical study, first announced on November 2nd 2022, is actively recruiting patients. Approximately 40 participants are needed from a single research centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Drug Interaction Study of LY3871801 in Healthy Participants

2022. "A Drug Interaction Study of LY3871801 in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05602675.